Metabolism Platform

GemPharmatech provides animal disease models and genetically humanized models for metabolic diseases, including diabetes mellitus, abnormal lipid metabolism, obesity, and NASH. The company additionally provides a series of in vivo R&D services, with corresponding disease models selected in light of the mechanism of action of the investigational drug.

These models include histopathological analysis, detection of metabolism-related cytokines and inflammatory factors, body weight and food intake, blood glucose, glycosylated haemoglobin (HbA1c), plasma insulin, GTT, and ITT, as well as body composition, bone density, and both indirect and direct metabolic cage tests, which monitor for factors such as CO2  and O2  production, heat, RER and activity, or urine and fecal collection.

英文官网图片修改-02(5)(3).jpg

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.